Employing both genetic and pharmacological approaches, we provide evidence that targeting FOXD1 stabilization through USP21 inhibition may thus open an avenue for therapeutic intervention in GBMs, particularly in patients with therapy-resistant MES subtypes. Here, FOXD1 is linked to Meckel syndrome, type 1.